- Shot prevents severe disease, but more data needed on over-55s.
- Many scientists underline limitations of the vaccine.
- They are going slow with the approval to get more data on elderly and severe patients.
- So far there is a lack of clarity because of varied data.
According to a Bloomberg report, on the day Britain began immunizing its population with a Covid-19 shot developed by Germany’s BioNTech SE and the U.S.’s Pfizer Inc., a peer-reviewed study of the U.K.’s homegrown vaccine left some...
https://mfame.guru/oxford-vaccine-effectivity-on-elderly-severe-covid-patients-slows-approval/